Neoadjuvant therapy in pancreatic cancer: a review and update on recent trials
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Neoadjuvant therapy in pancreatic cancer: a review and update on recent trials
Authors
Keywords
-
Journal
CURRENT OPINION IN GASTROENTEROLOGY
Volume 38, Issue 5, Pages 521-531
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2022-07-27
DOI
10.1097/mog.0000000000000874
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial
- (2022) Eva Versteijne et al. JOURNAL OF CLINICAL ONCOLOGY
- LBA57 Unicancer PRODIGE 24/CCTG PA6 trial: Updated results of a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX (mFFX) versus gemcitabine (gem) in patients (pts) with resected pancreatic ductal adenocarcinomas (PDAC)
- (2021) T. Conroy et al. ANNALS OF ONCOLOGY
- Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer
- (2021) Roberto Alva-Ruiz et al. ANNALS OF SURGICAL ONCOLOGY
- A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial contact
- (2021) Naru Kondo et al. EUROPEAN JOURNAL OF CANCER
- Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study
- (2020) Philip A Philip et al. Lancet Gastroenterology & Hepatology
- GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer
- (2020) Grainne M. O'Kane et al. CLINICAL CANCER RESEARCH
- Neoadjuvant‐modified FOLFIRINOX vs nab‐paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection
- (2020) Adam R. Wolfe et al. Cancer Medicine
- Surgical Outcome Results From SWOG S1505
- (2020) Syed A. Ahmad et al. ANNALS OF SURGERY
- Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma
- (2020) Giampaolo Perri et al. JAMA Surgery
- Total Neoadjuvant Therapy for Operable Pancreatic Cancer
- (2020) Rebecca Y. Kim et al. ANNALS OF SURGICAL ONCOLOGY
- A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects with Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
- (2020) D Brock Hewitt et al. ANNALS OF SURGERY
- Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine
- (2020) R. Casolino et al. ANNALS OF ONCOLOGY
- Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial
- (2020) Volker Kunzmann et al. Lancet Gastroenterology & Hepatology
- Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer
- (2019) Mark J. Truty et al. ANNALS OF SURGERY
- Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer
- (2019) Janet E. Murphy et al. JAMA Oncology
- Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer
- (2018) Jin-Young Jang et al. ANNALS OF SURGERY
- Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma
- (2018) Janet E. Murphy et al. JAMA Oncology
- A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma
- (2018) Susan Tsai et al. ANNALS OF SURGERY
- FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
- (2018) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
- (2017) John P Neoptolemos et al. LANCET
- Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib
- (2016) Pascal Hammel et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer
- (2016) Matthew H. G. Katz et al. JAMA Surgery
- Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer
- (2013) Helmut Oettle et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid or Gemcitabine vs Observation on Survival in Patients With Resected Periampullary Adenocarcinoma
- (2012) John P. Neoptolemos et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started